LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research


VL50 is a platform technology pioneering computational and experimental approaches to uncover, target, and harness post-transcriptional modifications as novel therapeutics, based on strong foundational IP developed within the Flagship Pioneering innovation foundry. VL50 follows in the footsteps of VentureLabs companies such as Moderna Therapeutics, Seres Therapeutics, Rubius Therapeutics, and Evelo Therapeutics.

VL50 logo
Website - Coming Soon
  • Avak Kahvejian, PhD
  • Nicholas Plugis, PhD